Add BrightSurf on Google Email

Common therapy for HIV associated with cervical abnormality regression

A study by Johns Hopkins Bloomberg School of Public Health found that Highly Active Antiretroviral Therapy (HAART) improved the regression rates of cervical squamous intraepithelial lesions (SIL) in HIV-positive women. However, a significant proportion of high-risk lesions persisted even among those who received HAART.

SourceJournal of the National Cancer Institute·JournalJNCI Journal of the National Cancer Institute·DateJul 20, 2004

Africans take anti-HIV meds at a higher rate than many anticipated

In a study published in the Journal of Acquired Immune Deficiency Syndromes, researchers found that African participants took on average 91-94% of prescribed HIV medications. The study, which followed 34 participants over 12 weeks, used multiple adherence measures and observed high rates of viral suppression.

SourceUniversity of California - San Francisco·JournalJAIDS Journal of Acquired Immune Deficiency Syndromes·DateJul 13, 2004
SAMSUNG T9 Portable SSD 2TB

SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.

AIDS: A single-tablet generic tritherapy

A clinical trial in Cameroon shows a generic fixed-dose antiretroviral tritherapy to be as effective as conventional therapies, with good patient compliance and high quality of the treatment. The treatment, which costs $20 per month, is well tolerated and provides a cost-effective solution for HIV treatment in developing countries.

SourceInstitut de recherche pour le développement·JournalThe Lancet·DateJul 1, 2004
Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

HIV/AIDS issue: July 3, 2004

The Lancet discusses new design changes to the journal, including open-access policies and electronic document posting. The article also explores various HIV/AIDS strategies for developing countries, including expanded access to treatment and prevention efforts. Researchers emphasize the importance of local solutions and community-led ...

SourceThe Lancet_DELETED·JournalThe Lancet·DateJul 1, 2004

Weekly cycles of once-daily anti-HIV drugs could reduce cost of HIV treatment

Researchers found that a weekly cycle of once-daily anti-HIV drugs can effectively treat HIV infection while reducing medication costs. The study involved eight patients who received a treatment regimen of 7 days on, followed by 7 days off, and maintained undetectable levels of HIV in their bloodstream for up to 84 weeks.

SourceNIH/National Institute of Allergy and Infectious Diseases·JournalThe Journal of Infectious Diseases·DateMay 20, 2004

HIV drug content in developing countries meets U.S. standards

A study by the Infectious Diseases Society of America found that HIV drugs from developing countries meet US standards for active ingredient levels. Bioequivalency studies are still necessary to ensure efficacy and safety, according to lead author Dr. Scott Penzak.

SourceInfectious Diseases Society of America·JournalClinical Infectious Diseases·DateApr 16, 2004
Davis Instruments Vantage Pro2 Weather Station

Davis Instruments Vantage Pro2 Weather Station offers research-grade local weather data for networked stations, campuses, and community observatories.

Combination, order of anti-HIV drugs make a difference in first-time recipients

Researchers found that starting with a combination of zidovudine, lamivudine, and efavirenz resulted in delayed failure of subsequent regimens and lower risk of drug resistance. The study suggests using sequential three-drug regimens may be more effective than four-drug treatments for treating first-time HIV recipients.

SourceNIH/National Institute of Allergy and Infectious Diseases·JournalNew England Journal of Medicine·DateDec 10, 2003
Celestron NexStar 8SE Computerized Telescope

Celestron NexStar 8SE Computerized Telescope combines portable Schmidt-Cassegrain optics with GoTo pointing for outreach nights and field campaigns.

FDA approves new HIV protease inhibitor, Lexiva (TM)

Lexiva demonstrated durable anti-viral response through 48 weeks, significantly less grade 2-4 drug-related diarrhea than nelfinavir. In PI-experienced patients, Lexiva/r showed fewer nucleoside reverse transcriptase inhibitor (NRTI) mutations after virologic failure compared to lopinavir/ritonavir.

SourcePublic Communications Inc.·DateOct 21, 2003

Antiretroviral therapy after birth decreases mother-to-child HIV transmission

A study published in The Lancet found that administering nevirapine and zidovudine to babies after birth can significantly reduce mother-to-child HIV transmission. The regimen resulted in a 7% protection rate for infants who received the full course, compared to 12% for those who only received nevirapine.

SourceJohns Hopkins Bloomberg School of Public Health·JournalThe Lancet·DateOct 9, 2003

Study assessing once daily Abacavir (ABC) in a once daily ART regimen

A multicenter study of 770 individuals found that a once-daily Abacavir regimen achieved similar virologic responses as the traditional twice-daily dosing regimen, with 66% achieving undetectable HIV-1 RNA levels. The regimen was also found to have a similar safety profile, with minimal hypersensitivity reactions reported.

SourcePublic Communications Inc.·DateSep 16, 2003
Garmin GPSMAP 67i with inReach

Garmin GPSMAP 67i with inReach provides rugged GNSS navigation, satellite messaging, and SOS for backcountry geology and climate field teams.

Most resistance to Anti-HIV drugs created by good pill-taking patients

Research at UCSF found that patients taking 80% or more of their antiretroviral medications developed twice as many resistance mutations as those taking less than 40%. Despite this, excellent adherence remains the best way to prevent HIV/AIDS and prolong life with resistant virus.

SourceUniversity of California - San Francisco·JournalAIDS·DateAug 20, 2003

Hope for South Africa - at last

A new grant of US$41 million from the Global Fund will support HIV/AIDS treatment and prevention in South Africa over 2 years. Generic antiretrovirals will be developed and produced locally, offering affordable access to life-saving medications.

SourceThe Lancet_DELETED·JournalThe Lancet·DateAug 14, 2003
Fluke 87V Industrial Digital Multimeter

Fluke 87V Industrial Digital Multimeter is a trusted meter for precise measurements during instrument integration, repairs, and field diagnostics.

Revised guidelines will ease selection of HIV/AIDS treatments

The updated Guidelines provide practitioners with a list of suggested combination regimens for the initiation of antiretroviral therapy, taking into consideration factors such as potency, toxicities, and dosing frequency. The revised document aims to simplify the process of selecting an effective treatment regimen for HIV/AIDS patients.

SourceNIH/National Institute of Allergy and Infectious Diseases·DateJul 14, 2003
Nikon Monarch 5 8x42 Binoculars

Nikon Monarch 5 8x42 Binoculars deliver bright, sharp views for wildlife surveys, eclipse chases, and quick star-field scans at dark sites.

Half of HIV patients choose alternative medicine

A study of 2,466 HIV-positive adults reveals that 53% use alternative medicine, often without informing their doctors. This can lead to adverse interactions with conventional treatment and increased risk of treatment failure.

SourceUniversity of California - Los Angeles·JournalJAIDS Journal of Acquired Immune Deficiency Syndromes·DateJun 19, 2003

New drug enfuvirtide shows promise against drug resistant HIV infection

A new class of anti-HIV medication, developed by Trimeris, has shown significant improvement in virologic and immunologic responses in patients with drug-resistant HIV. Enfuvirtide (T-20) works by blocking HIV entry into CD4 + lymphocytes and can benefit patients who already have HIV resistant to current therapy.

SourceUniversity of North Carolina at Chapel Hill·JournalNew England Journal of Medicine·DateMay 28, 2003

Global fight against AIDS requires more than drug cocktails

The editorial emphasizes that providing affordable drugs is insufficient to combat HIV in the developing world. Comprehensive medical care, including training for healthcare workers and laboratory tests, must also be included to make Highly Active Antiretroviral Therapy (HAART) effective.

SourceJohns Hopkins Medicine·JournalNew England Journal of Medicine·DateApr 30, 2003

HIV drugs not causing rise in vascular disease

A recent study analyzed data from the Veterans Affairs HIV patient population between 1993 and 2001 and found a sharp decline in overall death rates among patients. Despite concerns about vascular disease as a side effect of HAART, the study suggests that these drugs may not increase the risk of this condition.

SourceVeterans Affairs Research Communications·JournalNew England Journal of Medicine·DateFeb 19, 2003
Apple MacBook Pro 14-inch (M4 Pro)

Apple MacBook Pro 14-inch (M4 Pro) powers local ML workloads, large datasets, and multi-display analysis for field and lab teams.

Guidelines issued for metabolic complications related to HIV & antiretrovirals

The new guidelines identify five major areas of concern: insulin resistance, lipid metabolism, lactic acid disorders, bone disease, and abnormal body fat distribution. These metabolic complications may increase the risk of heart disease, stroke, and potentially fatal lactic acidosis.

SourceUniversity of California - San Francisco·JournalJAIDS Journal of Acquired Immune Deficiency Syndromes·DateNov 4, 2002
Meta Quest 3 512GB

Meta Quest 3 512GB enables immersive mission planning, terrain rehearsal, and interactive STEM demos with high-resolution mixed-reality experiences.

GQ GMC-500Plus Geiger Counter

GQ GMC-500Plus Geiger Counter logs beta, gamma, and X-ray levels for environmental monitoring, training labs, and safety demonstrations.

Sony Alpha a7 IV (Body Only)

Sony Alpha a7 IV (Body Only) delivers reliable low-light performance and rugged build for astrophotography, lab documentation, and field expeditions.

Cocaine use linked to poor adherence to antiretroviral therapy in HIV patients

A study by the NIH/National Institute on Drug Abuse found that active cocaine users had significantly lower adherence rates to antiretroviral therapy, leading to a higher risk of viral suppression failure. The study suggests that interventions should include assessing and treating cocaine use in patients with HIV infection.

SourceNIH/National Institute on Drug Abuse·JournalJournal of General Internal Medicine·DateJun 27, 2002

UCSF health economists urge global AIDS fund to finance prevention first

UCSF researchers argue that funding HIV prevention interventions in sub-Saharan Africa is 28 times more cost-effective than treating individuals with highly active antiretroviral therapy (HAART). Implementing six proven prevention interventions can save a maximum number of lives with limited funds available, according to the study.

SourceUniversity of California - San Francisco·JournalThe Lancet·DateMay 23, 2002
Aranet4 Home CO2 Monitor

Aranet4 Home CO2 Monitor tracks ventilation quality in labs, classrooms, and conference rooms with long battery life and clear e-ink readouts.

Minority Medicaid recipients least likely to be on most effective AIDS drugs

A study found significant disparities in HIV/AIDS treatment among minority Medicaid recipients, with African Americans waiting longer to start life-saving treatments and Hispanics being less likely to stay on them. The researchers suggest that improved care strategies and supportive services are needed to address these disparities.

SourceCenter for Advancing Health·JournalJournal of General Internal Medicine·DateDec 5, 2001

Garlic supplements can impede HIV medication

Researchers discovered that garlic supplements decreased saquinavir levels by up to 51% in healthy volunteers. This suggests that patients taking saquinavir should avoid using garlic supplements to prevent interactions.

SourceNIH/National Institute of Allergy and Infectious Diseases·JournalClinical Infectious Diseases·DateDec 5, 2001

7-day-on, 7-day-off regimen could reduce cost, toxicities of HIV therapy

Researchers suggest a structured intermittent therapy approach, where patients receive daily doses of HAART for seven days, followed by seven days off the medication. This regimen has shown significant reductions in certain side effects, including cholesterol and triglyceride levels, without compromising treatment efficacy.

SourceNIH/National Institute of Allergy and Infectious Diseases·JournalProceedings of the National Academy of Sciences·DateDec 3, 2001

New finding may help doctors prevent HIV drug resistance

Researchers at NIAID and NCI discovered a quick and simple method to assess drug efficacy by measuring viral load after just one week of therapy. This approach has the potential to prevent HIV drug resistance and improve treatment outcomes for patients.

SourceNIH/National Institute of Allergy and Infectious Diseases·JournalThe Lancet·DateNov 22, 2001
Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C)

Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C) keeps Macs, tablets, and meters powered during extended observing runs and remote surveys.

Female genital shedding of HIV-1 poses infection risk

A study found that HIV-1 shedding in female genital secretions is common, with 57% of women having RNA present. High plasma RNA concentrations are the best predictor for risk of transmission. Women on antiretroviral therapy may still be at risk of transmitting the virus to their partners or babies.

SourceThe Lancet_DELETED·JournalThe Lancet·DateNov 8, 2001

UCLA scientists discover stress accelerates AIDS progression, undermines anti-HIV drugs' effect

A study of 13 HIV-positive men found that those with high levels of autonomic nervous system activity responded less well to antiretroviral treatment, with some experiencing no immune recovery. Stress accelerates AIDS progression by increasing viral replication and making it harder for the body to fight off the infection.

SourceUniversity of California - Los Angeles·JournalProceedings of the National Academy of Sciences·DateOct 30, 2001
GoPro HERO13 Black

GoPro HERO13 Black records stabilized 5.3K video for instrument deployments, field notes, and outreach, even in harsh weather and underwater conditions.

Adverse effects of antiretroviral treatment for HIV infection

A recent study published in The Lancet found that nearly half of people receiving antiretroviral treatment for HIV-1 developed clinical adverse effects, while 27% experienced laboratory adverse effects. The authors emphasize the need for postmarketing surveillance to improve tolerability of anti-HIV-1 treatment.

SourceThe Lancet_DELETED·JournalThe Lancet·DateOct 18, 2001

Researchers examine the use of antiretroviral therapy among injection drug users with HIV infection: Study suggests addiction treatment and health care contribute to HAART enrollment

A study by Johns Hopkins Bloomberg School of Public Health found that nearly one third of eligible injection drug users never received antiretroviral treatment. Methadone addiction treatment, health insurance, and regular access to care were associated with increased HAART use among men.

SourceJohns Hopkins Bloomberg School of Public Health·JournalAIDS·DateSep 25, 2001

Effective treatments lacking for most desperate AIDS patients

AIDS researchers urge collaboration to develop new treatments for drug-resistant HIV patients, who represent 30% of treated cases in the US. The lack of effective therapies sets the stage for a dangerous epidemic of drug-resistant HIV.

SourceUniversity of Pittsburgh Medical Center·JournalNew England Journal of Medicine·DateAug 8, 2001
Sky-Watcher EQ6-R Pro Equatorial Mount

Sky-Watcher EQ6-R Pro Equatorial Mount provides precise tracking capacity for deep-sky imaging rigs during long astrophotography sessions.

New approaches to hiv treatment in less developed countries

Researchers propose integrating highly-active antiretroviral therapy (HAART) into existing tuberculosis-control infrastructure in less-developed countries. Directly-observed therapy has shown effectiveness in resource-poor settings with sustained commitment to uninterrupted care that is free to the patient.

SourceThe Lancet_DELETED·JournalThe Lancet·DateAug 2, 2001
Apple Watch Series 11 (GPS, 46mm)

Apple Watch Series 11 (GPS, 46mm) tracks health metrics and safety alerts during long observing sessions, fieldwork, and remote expeditions.

Study evaluates dosage adjustments of Agenerase

A study evaluated dosage adjustments of Agenerase in HIV patients taking efavirenz or nevirapine, showing that therapeutic plasma concentrations were maintained at 6 or 12 weeks. Dosage adjustments resulted in improved amprenavir levels in all cases, despite the presence of efavirenz or nevirapine.

SourcePublic Communications Inc.·DateSep 18, 2000

Study compares efficacy and adherence to triple nucleoside therapy Ziagen + Combivir with protease inhibitor plus Combivir regimens in therapy-nave

A study found that 74% of patients taking Ziagen/Combivir had viral loads below 400 copies/ml at 24 weeks, compared to 57% on the PI-containing regimen. Patients on Ziagen/Combivir also reported fewer difficulties with their triple regimen. The study assessed efficacy, safety, and patient adherence in therapy-naive patients.

SourcePublic Communications Inc.·DateSep 17, 2000
Apple AirPods Pro (2nd Generation, USB-C)

Apple AirPods Pro (2nd Generation, USB-C) provide clear calls and strong noise reduction for interviews, conferences, and noisy field environments.